Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...On Thursday, he could find comfort in at least one public show of support from top three shareholder Harris Associates, which said Anderson was “absolutely taking the right path to enhance value creation...
...“There are 220 diseases that you can associate with obesity . . . in the future, there needs to be more choices,” he said....
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...Its proposition, coupling its traditional behaviour-change programme with medication where appropriate, is backed by multiple medical studies, said Fatima Cody Stanford, an obesity medicine physician and associate...
...A Humira biosimilar from Teva Pharmaceuticals working with Alvotech earlier this year became the first drug that the US Food and Drug Administration granted interchangeable status, which lets pharmacists...
Admonitions about staff trading in their employer’s shares may now need to be broadened
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...“It was one of the most epic episodes ever in pharmaceuticals history: you got an accelerated approval of a product that didn’t have a completed phase 3 trial....
US healthcare company is putting cash to work from spinning off its consumer health arm
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
A weight loss titan fights to stay relevant in the age of GLP-1 drugs
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
...“What is most important is that it kills antibiotic-resistant strains in animals,” said Yury Polikanov, co-author of the research and an associate professor of biological sciences at the University of Illinois...
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...“This means further deceleration from the highs of 2022 when close to 65 per cent of all flows into the European ETF market were directed to ESG-themed strategies,” said Jose Garcia-Zarate, associate director...
...Intas has since resumed supply of oncology drugs to the US but Valerie Jensen, associate director of the FDA’s drug shortages staff, says the company and its competitors have not been able to ramp up capacity...
...Richard Oakley, associate director of research and innovation at the UK’s Alzheimer’s Society, said the study was a “hugely welcome step in the right direction” because it appeared to be as accurate as the...
...The 467 signatories said the process to appoint the new editors was “not appropriate, consistent, transparent or inclusive”, while it said former associate editors had received papers “to process that do...
...Immediately after learning this information, Bechtolsheim allegedly traded Acacia options in the accounts of a close relative and an associate....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Tim Carter, managing associate in the intellectual property team of law firm Addleshaw Goddard, said in an analysis of the ruling that it showed EUIPO was not going to allow this kind of commercial exploitation...
...Companies were reassessing priority areas for investment and cutting positions in costly but non-core divisions, said Daniel Keum, associate professor of management at Columbia Business School, such as Amazon...
US drugmaker is trying to chart its future without blockbuster Covid-19 products
International Edition